NCT06650423
Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer No drug interventions Not Available Not Available not_yet_recruiting NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer treatment 2 recruiting NCT05735080
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients with Advanced Cancer treatment 1 / 2 recruiting NCT04134884
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer treatment 1 completed NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer treatment 2 recruiting NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy treatment 2 recruiting NCT02387099
Dose EScalation Induction of EvERolimus treatment 2 completed NCT03874325
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer treatment 2 terminated NCT03906669
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. treatment 2 recruiting NCT02441946
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer treatment 2 completed NCT03910712
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC treatment 2 unknown_status NCT04088110
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer treatment 2 unknown_status NCT02730923
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) treatment 1 / 2 active_not_recruiting NCT04161833
Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) No drug interventions supportive_care Not Available completed NCT02404051
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer treatment 3 unknown_status NCT03462251
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line treatment 3 completed NCT04352777
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer treatment 2 active_not_recruiting NCT03409198
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer treatment 2 completed NCT02894398
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant treatment 2 completed NCT02592083
Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors treatment 2 active_not_recruiting NCT03691311
Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer treatment 0 unknown_status NCT05982093
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer treatment 2 recruiting NCT03809988
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) treatment 2 completed NCT05759949
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors treatment 1 active_not_recruiting NCT03917082
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer treatment 2 active_not_recruiting NCT03904173
Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT03407768
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer No drug interventions treatment Not Available active_not_recruiting